REGENERON PHARMACEUTICALS, INC.
Tremor tracks 56 of its cancer trials. This is a large company with many drugs, so one trial matters less to it, and company-wide signals count for half.
Company-wide warning signs
These add points to every one of this company's trials.
- 5 insiders sold shares within a monthSince Nov 4, 2026+4.8
Trials
- REGNRegeneron Pharmaceuticals15Calm
A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis
Running, no new patientsPhase 3288 patientsMain results: Jul 8, 2025 - REGNRegeneron Pharmaceuticals15Calm
First In Human (FIH) Study of REGN5459 in Adult Patients With Relapsed or Refractory Multiple Myeloma (MM)
FinishedPhase 1/243 patientsMain results: May 1, 2025 - REGNRegeneron Pharmaceuticals15Calm
Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients
Running, no new patientsPhase 265 patientsMain results: Mar 31, 2025 - REGNRegeneron Pharmaceuticals5Calm
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
Signing up patientsPhase 3560 patientsMain results: Mar 22, 2027 - REGNRegeneron Pharmaceuticals5Calm
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
Running, no new patientsPhase 1/2148 patientsMain results: Nov 2, 2035 - REGNRegeneron Pharmaceuticals5Calm
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
Signing up patientsPhase 3410 patientsMain results: Apr 19, 2033 - REGNRegeneron Pharmaceuticals5Calm
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
Signing up patientsPhase 2397 patientsMain results: Jun 30, 2028 - REGNRegeneron Pharmaceuticals5Calm
A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma
Signing up patientsPhase 1/2150 patientsMain results: Sep 30, 2033 - REGNRegeneron Pharmaceuticals5Calm
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
Signing up patientsPhase 3975 patientsMain results: Jul 31, 2028 - REGNRegeneron Pharmaceuticals5Calm
Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic Cancers
Signing up patientsPhase 31,600 patientsMain results: Jul 18, 2031 - REGNRegeneron Pharmaceuticals5Calm
REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis
Signing up patientsPhase 31,120 patientsMain results: Jan 23, 2030 - REGNRegeneron Pharmaceuticals5Calm
A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
Signing up patientsPhase 1/2345 patientsMain results: Nov 15, 2027 - REGNRegeneron Pharmaceuticals5Calm
A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
Signing up patientsPhase 3915 patientsMain results: May 21, 2029 - REGNRegeneron Pharmaceuticals5Calm
A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
Signing up patientsPhase 3270 patientsMain results: Jul 27, 2033 - REGNRegeneron Pharmaceuticals5Calm
A Study to Investigate Mibavademab in Adult Women With Functional Hypothalamic Amenorrhea
Signing up patientsPhase 234 patientsMain results: Jan 28, 2028 - REGNRegeneron Pharmaceuticals5Calm
A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
Signing up patientsPhase 3904 patientsMain results: Mar 30, 2028 - REGNRegeneron Pharmaceuticals5Calm
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
Running, no new patientsPhase 2184 patientsMain results: Dec 4, 2029 - REGNRegeneron Pharmaceuticals5Calm
A Study Comparing Cemiplimab-based Treatments for Adult Participants With Locally Advanced Basal Cell Skin Cancer (laBCC)
Not started yetPhase 2135 patientsMain results: Nov 13, 2030 - REGNRegeneron Pharmaceuticals5Calm
Linvoseltamab Versus Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone (Dara-Vcd) in Adult Participants With Newly Diagnosed Systemic Light Chain Amyloidosis
Not started yetPhase 3382 patientsMain results: Jul 25, 2035 - REGNRegeneron Pharmaceuticals5Calm
Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma
Signing up patientsPhase 1/2387 patientsMain results: Mar 30, 2033 - REGNRegeneron Pharmaceuticals5Calm
A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
Signing up patientsPhase 2300 patientsMain results: Jun 10, 2030 - REGNRegeneron Pharmaceuticals5Calm
A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Signing up patientsPhase 2120 patientsMain results: Jun 4, 2028 - REGNRegeneron Pharmaceuticals5Calm
REGN9220 in Combination With Odronextamab in Adult Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphomas (BCNHLs)
Not started yetPhase 1/236 patientsMain results: Nov 1, 2029 - REGNRegeneron Pharmaceuticals5Calm
A Study to Evaluate Cenvacibart (REGN7508) for Secondary Stroke Prevention in Adult Participants
Not started yetPhase 36,106 patientsMain results: Dec 15, 2029 - REGNRegeneron Pharmaceuticals5Calm
A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma
Signing up patientsPhase 3580 patientsMain results: Apr 30, 2031 - REGNRegeneron Pharmaceuticals5Calm
Safety and Efficacy Study in Adults With Advanced Solid Tumors Receiving REGN13089-M404-M2980, an Antibody-drug Conjugate That Targets MET Protein on Tumors
Not started yetPhase 1/2320 patientsMain results: Mar 10, 2031 - REGNRegeneron Pharmaceuticals5Calm
A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma
Signing up patientsPhase 3822 patientsMain results: Feb 7, 2028 - REGNRegeneron Pharmaceuticals5Calm
REGN21353 Alone or in Combination With Nezastomig for Metastatic Castration-Resistant Prostate Cancer in Adult Participants
Not started yetPhase 1/2192 patientsMain results: Jul 28, 2031 - REGNRegeneron Pharmaceuticals5Calm
REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma
Signing up patientsPhase 1/2265 patientsMain results: Oct 27, 2030 - REGNRegeneron Pharmaceuticals5Calm
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
Signing up patientsPhase 1/2890 patientsMain results: May 10, 2027 - REGNRegeneron Pharmaceuticals5Calm
A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
Signing up patientsPhase 1/2612 patientsMain results: Nov 8, 2028 - REGNRegeneron Pharmaceuticals5Calm
Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma
Signing up patientsPhase 3369 patientsMain results: May 3, 2030 - REGNRegeneron Pharmaceuticals5Calm
A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer
Running, no new patientsPhase 1/295 patientsMain results: Jul 6, 2027 - REGNRegeneron Pharmaceuticals5Calm
A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
Signing up patientsPhase 1/2220 patientsMain results: Aug 20, 2028 - REGNRegeneron Pharmaceuticals5Calm
A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery
Running, no new patientsPhase 2195 patientsMain results: Aug 24, 2026 - REGNRegeneron Pharmaceuticals5Calm
A Study of DB-OTO, an Adeno-Associated Virus (AAV) Based Gene Therapy, in Children/Infants, Adolescents and Adults With Hearing Loss Due to Otoferlin Mutations
Signing up patientsPhase 1/236 patientsMain results: Feb 26, 2029 - REGNRegeneron Pharmaceuticals5Calm
A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants With Relapsed/Refractory Multiple Myeloma
Signing up patientsPhase 1/2186 patientsMain results: Nov 11, 2033 - REGNRegeneron Pharmaceuticals5Calm
A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies
Running, no new patientsPhase 2515 patientsMain results: Jun 17, 2026 - REGNRegeneron Pharmaceuticals5Calm
A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer
Running, no new patientsPhase 2/3160 patientsMain results: Jan 16, 2030 - REGNRegeneron Pharmaceuticals5Calm
A Study to Learn About the Long-Term Health of Adult Participants From a Previous Study of a New Melanoma Treatment
Invite-only sign-upPhase 248 patientsMain results: Oct 10, 2029 - REGNRegeneron Pharmaceuticals5Calm
A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma
Signing up patientsPhase 2116 patientsMain results: May 18, 2032 - REGNRegeneron Pharmaceuticals5Calm
A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery
Running, no new patientsPhase 31,564 patientsMain results: Jul 27, 2026 - REGNRegeneron Pharmaceuticals5Calm
A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)
Running, no new patientsPhase 2/3149 patientsMain results: Sep 28, 2027 - REGNRegeneron Pharmaceuticals5Calm
A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers
Running, no new patientsPhase 1/2548 patientsMain results: Nov 13, 2026 - REGNRegeneron Pharmaceuticals5Calm
Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)
FinishedPhase 3712 patientsMain results: Apr 18, 2025 - REGNRegeneron Pharmaceuticals5Calm
Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer
FinishedPhase 3789 patientsMain results: Feb 27, 2025 - REGNRegeneron Pharmaceuticals5Calm
A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma
Running, no new patientsPhase 3216 patientsMain results: May 29, 2028 - REGNRegeneron Pharmaceuticals5Calm
A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1)
Running, no new patientsPhase 251 patientsMain results: Jan 26, 2028 - REGNRegeneron Pharmaceuticals5Calm
A Safety and Efficacy Study of Combined Fianlimab + Cemiplimab in Children and Young Adults With Recurrent or Progressive High-Grade Glioma or Posterior Fossa-A Ependymoma
Not started yetPhase 1/2120 patientsMain results: Aug 27, 2032 - REGNRegeneron Pharmaceuticals5Calm
A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With REGN5678 for Adult Participants With Advanced Prostate Cancer
Signing up patientsPhase 1/2228 patientsMain results: Mar 28, 2030 - REGNRegeneron Pharmaceuticals5Calm
A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body
Signing up patientsPhase 1/2240 patientsMain results: Feb 3, 2030 - REGNRegeneron Pharmaceuticals5Calm
Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma
Running, no new patientsPhase 31,546 patientsMain results: Mar 12, 2026 - REGNRegeneron Pharmaceuticals5Calm
A Proof-of-Concept Trial to Study the Safety and Activity of Linvoseltamab in Adult Participants With Smoldering Multiple Myeloma at High Risk of Developing Multiple Myeloma
Running, no new patientsPhase 240 patientsMain results: Jan 25, 2033 - REGNRegeneron Pharmaceuticals5Calm
Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma
Running, no new patientsPhase 3415 patientsMain results: Jan 7, 2028 - REGNRegeneron Pharmaceuticals5Calm
A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma
Running, no new patientsPhase 2151 patientsMain results: Nov 2, 2026 - REGNRegeneron Pharmaceuticals5Calm
A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma
Running, no new patientsPhase 3733 patientsMain results: Jul 29, 2029
Key executives leaving
From the last 12 months of the company's SEC reports.
Insider trades (last 6 months)
“Insiders” are executives, board members, and big shareholders. Many of their sales are pre-planned: scheduled months ahead under a legal plan (called 10b5-1), so they usually say little. Tremor only counts sales that weren't pre-planned.
63 sales (27 not pre-planned) · 0 purchases
- Pitofsky JasonSVP Controller · Nov 4, 2026Sold 439 sharesabout $412 thousand · not pre-planned
- Pitofsky JasonSVP Controller · Nov 4, 2026Sold 575 sharesabout $541 thousand · not pre-planned
- Pitofsky JasonSVP Controller · Nov 4, 2026Sold 982 sharesabout $925 thousand · not pre-planned
- Pitofsky JasonSVP Controller · Nov 4, 2026Sold 1,215 sharesabout $1.1 million · not pre-planned
- Pitofsky JasonSVP Controller · Nov 4, 2026Sold 529 sharesabout $499 thousand · not pre-planned
- Pitofsky JasonSVP Controller · Nov 4, 2026
Recent SEC filings
Public companies must report important news and their finances to the SEC, the US agency that oversees the stock market.
- Quarterly reportQuarterly report (10-Q)Oct 30, 2026
- Shared quarterly resultsNews report (8-K)Oct 30, 2026
- Signed a major agreement; Shared quarterly results; Other newsNews report (8-K)Oct 6, 2026
- An executive or board member joined or leftNews report (8-K)Sep 30, 2026
- Quarterly reportQuarterly report (10-Q)Jul 30, 2026